Anti-inflammatory and metabolic actions of FXR: Insights into molecular mechanisms

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1821, Issue 11, 2012, Pages 1443-1452

  Hollman, Danielle A A ^a   Milona, Alexandra ^a   Van Erpecum, Karel J ^a   Van Mil, Saskia W C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

FXR; Nuclear receptor; Post translational modification; Selective ligand; Transactivation; Transrepression

Indexed keywords

FARNESOID X RECEPTOR; FARNESOID X RECEPTOR AGONIST; HORMONE RECEPTOR STIMULATING AGENT; OBETICHOLIC ACID; PX 102; TUROFEXORATE ISOPROPYL; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; BILE ACID METABOLISM; DRUG EFFECT; GENE CONTROL; GENE TARGETING; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; LIPID METABOLISM; METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SUMOYLATION; TRANSACTIVATION;

ANTI-INFLAMMATORY AGENTS; BILE ACIDS AND SALTS; HUMANS; INFLAMMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA-BINDING PROTEINS;

EID: 84865484646     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2012.07.004     Document Type: Review

References (106)

1. A. Chawla, J.J. Repa, R.M. Evans, and D.J. Mangelsdorf Nuclear receptors and lipid physiology: opening the X-files Science 294 2001 1866
2. W. Bourguet, V. Vivat, J.M. Wurtz, P. Chambon, H. Gronemeyer, and D. Moras Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains Mol. Cell 5 2000 289 298
3. D.M. Lonard, and B.W. O'Malley Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation Mol. Cell 27 2007 691 700
4. D.J. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, and P. Chambon The nuclear receptor superfamily: the second decade Cell 83 1995 835 839
5. L. Nagy, and J.W.R. Schwabe Mechanism of the nuclear receptor molecular switch Trends Biochem. Sci. 29 2004 317 324
6. J.P. Overington, B. Al-Lazikani, and A.L. Hopkins How many drug targets are there? Nat. Rev. Drug Discov. 5 2006 993 996
7. L. Altucci, M.D. Leibowitz, K.M. Ogilvie, A.R. de Lera, and H. Gronemeyer RAR and RXR modulation in cancer and metabolic disease Nat. Rev. Drug Discov. 6 2007 793 810
8. G. Chinetti, S. Griglio, M. Antonucci, I.P. Torra, P. Delerive, Z. Majd, J.C. Fruchart, J. Chapman, J. Najib, and B. Staels Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages J. Biol. Chem. 273 1998 25573 25580
9. V.C. Jordan, and A.M.H. Brodie Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer Steroids 72 2007 7 25
10. J. Sonoda, L. Pei, and R.M. Evans Nuclear receptors: decoding metabolic disease FEBS Lett. 582 2008 2 9
11. J.M. Berg, and D.L. Merkle On the metal ion specificity of zinc finger proteins J. Am. Chem. Soc. 111 1989 3759 3761
12. W. Bourguet, M. Ruff, P. Chambon, H. Gronemeyer, and D. Moras Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α Nature 375 1995 377 382
13. A. Klug, and J.W. Schwabe Protein motifs 5. Zinc fingers FASEB J. 9 1995 597
14. J.M. Wurtz, W. Bourguet, J.P. Renaud, V. Vivat, P. Chambon, D. Moras, and H. Gronemeyer A canonical structure for the ligand-binding domain of nuclear receptors Nat. Struct. Mol. Biol. 3 1996 87 94
15. S. Ghisletti, W. Huang, S. Ogawa, G. Pascual, M.E. Lin, T.M. Willson, M.G. Rosenfeld, and C.K. Glass Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPAR [gamma] Mol. Cell 25 2007 57 70
16. G. Pascual, A.L. Fong, S. Ogawa, A. Gamliel, A.C. Li, V. Perissi, D.W. Rose, T. Willson, M.G. Rosenfeld, and C.K. Glass A sumoylation-dependent pathway mediating transrepression of inflammatory response genes by PPARgamma Nature 437 2005 759
17. M. Shimizu, D. Yamashita, T. Yamaguchi, F. Hirose, and T. Osumi Aspects of the regulatory mechanisms of PPAR functions: analysis of a bidirectional response element and regulation by sumoylation Mol. Cell. Biochem. 286 2006 33 42
18. Y.D. Wang, W.D. Chen, and W. Huang FXR, a target for different diseases Histol. Histopathol. 23 2008 621 627
19. P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels Role of bile acids and bile acid receptors in metabolic regulation Physiol. Rev. 89 2009 147
20. B. Goodwin, S.A. Jones, R.R. Price, M.A. Watson, D.D. McKee, L.B. Moore, C. Galardi, J.G. Wilson, M.C. Lewis, and M.E. Roth A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis Mol. Cell 6 2000 517 526
21. G. Zollner, M. Wagner, P. Fickert, A. Geier, A. Fuchsbichler, D. Silbert, J. Gumhold, K. Zatloukal, A. Kaser, H. Tilg, H. Denk, and M. Trauner Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver Am. J. Physiol. Gastrointest. Liver Physiol. 289 2005 G798 G805
22. M. Ananthanarayanan, N. Balasubramanian, M. Makishima, D.J. Mangelsdorf, and F.J. Suchy Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor J. Biol. Chem. 276 2001 28857
23. L. Huang, A. Zhao, J.L. Lew, T. Zhang, Y. Hrywna, J.R. Thompson, N. de Pedro, I. Royo, R.A. Blevins, and F. Pelaez Farnesoid X receptor activates transcription of the phospholipid pump MDR3 J. Biol. Chem. 278 2003 51085
24. P.C. Pircher, J.L. Kitto, M.L. Petrowski, R.K. Tangirala, E.D. Bischoff, I.G. Schulman, and S.K. Westin Farnesoid X receptor regulates bile acid-amino acid conjugation J. Biol. Chem. 278 2003 27703
25. O. Barbier, I.P. Torra, A. Sirvent, T. Claudel, C. Blanquart, D. Duran-Sandoval, F. Kuipers, V. Kosykh, J.C. Fruchart, and B. Staels FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity Gastroenterology 124 2003 1926 1940
26. N. Mano, K. Nishimura, T. Narui, S. Ikegawa, and J. Goto Characterization of rat liver bile acid acyl glucuronosyltransferase Steroids 67 2002 257 262
27. P.A. Dawson, M. Hubbert, J. Haywood, A.L. Craddock, N. Zerangue, W.V. Christian, and N. Ballatori The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter J. Biol. Chem. 280 2005 6960
28. J. Grober, I. Zaghini, H. Fujii, S.A. Jones, S.A. Kliewer, T.M. Willson, T. Ono, and P. Besnard Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene J. Biol. Chem. 274 1999 29749
29. T.T. Lu, M. Makishima, J.J. Repa, K. Schoonjans, T.A. Kerr, J. Auwerx, and D.J. Mangelsdorf Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors Mol. Cell 6 2000 507 515
30. F. Chen, L. Ma, P.A. Dawson, C.J. Sinal, E. Sehayek, F.J. Gonzalez, J. Breslow, M. Ananthanarayanan, and B.L. Shneider Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter J. Biol. Chem. 278 2003 19909 19916
31. E. Neimark, F. Chen, X. Li, and B.L. Shneider Bile acid-induced negative feedback regulation of the human ileal bile acid transporter Hepatology 40 2004 149 156
32. T. Inagaki, M. Choi, A. Moschetta, L. Peng, C.L. Cummins, J.G. McDonald, G. Luo, S.A. Jones, B. Goodwin, J.A. Richardson, R.D. Gerard, J.J. Repa, D.J. Mangelsdorf, and S.A. Kliewer Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis Cell Metab. 2 2005 217 225
33. M. Choi, A. Moschetta, A.L. Bookout, L. Peng, M. Umetani, S.R. Holmstrom, K. Suino-Powell, H.E. Xu, J.A. Richardson, R.D. Gerard, D.J. Mangelsdorf, and S.A. Kliewer Identification of a hormonal basis for gallbladder filling Nat. Med. 12 2006 1253 1255
34. X.Q. Chen, L.L. Wang, Q.W. Shan, Q. Tang, Y.N. Deng, S.J. Lian, and X. Yun A novel heterozygous NR1H4 termination codon mutation in idiopathic infantile cholestasis World J. Pediatr. 8 2012 67 71
35. S.W.C. van Mil, A. Milona, P.H. Dixon, R. Mullenbach, V.L. Geenes, J. Chambers, V. Shevchuk, G.E. Moore, F. Lammert, and A.G. Glantz Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy Gastroenterology 133 2007 507 516
36. S. Fiorucci, C. Clerici, E. Antonelli, S. Orlandi, B. Goodwin, B.M. Sadeghpour, G. Sabatino, G. Russo, D. Castellani, and T.M. Willson Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis J. Pharmacol. Exp. Ther. 313 2005 604
37. Y. Liu, J. Binz, M.J. Numerick, S. Dennis, G. Luo, B. Desai, K.I. MacKenzie, T.A. Mansfield, S.A. Kliewer, B. Goodwin, and S.A. Jones Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis J. Clin. Invest. 112 2003 1678 1687
38. S. Modica, M. Petruzzelli, E. Bellafante, S. Murzilli, L. Salvatore, N. Celli, T.G. Di, G. Palasciano, T. Moustafa, E. Halilbasic, M. Trauner, and A. Moschetta Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis Gastroenterology 142 2012 355 365
39. C. Stedman, C. Liddle, S. Coulter, J. Sonoda, J.G. Alvarez, R.M. Evans, and M. Downes Benefit of farnesoid X receptor inhibition in obstructive cholestasis Proc. Natl. Acad. Sci. U. S. A. 103 2006 11323 11328
40. M. Wagner, P. Fickert, G. Zollner, A. Fuchsbichler, D. Silbert, O. Tsybrovskyy, K. Zatloukal, G.L. Guo, J.D. Schuetz, F.J. Gonzalez, H.U. Marschall, H. Denk, and M. Trauner Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice Gastroenterology 125 2003 825 838
41. A. Moschetta, A.L. Bookout, and D.J. Mangelsdorf Prevention of cholesterol gallstone disease by FXR agonists in a mouse model Nat. Med. 10 2004 1352 1358
42. S. Modica, R.M. Gadaleta, and A. Moschetta Deciphering the nuclear bile acid receptor FXR paradigm Nucl. Recept. Signal. 8 2010 e005
43. K. Ma, P.K. Saha, L. Chan, and D.D. Moore Farnesoid X receptor is essential for normal glucose homeostasis J. Clin. Invest. 116 2006 1102
44. Y. Zhang, F.Y. Lee, G. Barrera, H. Lee, C. Vales, F.J. Gonzalez, T.M. Willson, and P.A. Edwards Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice Proc. Natl. Acad. Sci. U. S. A. 103 2006 1006 1011
45. R. Cao, Z.X. Cronk, W. Zha, L. Sun, X. Wang, Y. Fang, E. Studer, H. Zhou, W.M. Pandak, P. Dent, G. Gil, and P.B. Hylemon Bile acids regulate hepatic gluconeogenic genes and farnesoid X receptor via G(alpha)i-protein-coupled receptors and the AKT pathway J. Lipid Res. 51 2010 2234 2244
46. D. Wei, R. Tao, Y. Zhang, M.F. White, and X.C. Dong Feedback regulation of hepatic gluconeogenesis through modulation of SHP/Nr0b2 gene expression by Sirt1 and FoxO1 Am. J. Physiol. Endocrinol. Metab. 300 2011 E312 E320
47. B. Cariou, K. van Harmelen, D. Duran-Sandoval, T.H. van Dijk, A. Grefhorst, M. Abdelkarim, S. Caron, G. Torpier, J.C. Fruchart, and F.J. Gonzalez The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice J. Biol. Chem. 281 2006 11039
48. S. Cipriani, A. Mencarelli, G. Palladino, and S. Fiorucci FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats J. Lipid Res. 51 2010 771
49. I.R. Popescu, A. Helleboid-Chapman, A. Lucas, B. Vandewalle, J. Dumont, and E. Bouchaert The nuclear receptor FXR is expressed in pancreatic [beta]-cells and protects human islets from lipotoxicity FEBS Lett. 584 2010 2845 2851
50. M. Watanabe, Y. Horai, S.M. Houten, K. Morimoto, T. Sugizaki, E. Arita, C. Mataki, H. Sato, Y. Tanigawara, and K. Schoonjans Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure J. Biol. Chem. 286 2011 26913 26920
51. T. Claudel, Y. Inoue, O. Barbier, D. Duran-Sandoval, V. Kosykh, J. Fruchart, J.C. Fruchart, F.J. Gonzalez, and B. Staels Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression Gastroenterology 125 2003 544 555
52. H.R. Kast, C.M. Nguyen, C.J. Sinal, S.A. Jones, B.A. Laffitte, K. Reue, F.J. Gonzalez, T.M. Willson, and P.A. Edwards Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids Mol. Endocrinol. 15 2001 1720 1728
53. M. Watanabe, S.M. Houten, L. Wang, A. Moschetta, D.J. Mangelsdorf, R.A. Heyman, D.D. Moore, and J. Auwerx Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c J. Clin. Invest. 113 2004 1408 1418
54. R.M. Gadaleta, K.J. van Erpecum, B. Oldenburg, E.C.L. Willemsen, W. Renooij, S. Murzilli, L.W.J. Klomp, P.D. Siersema, M.E.I. Schipper, and S. Danese Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease Gut 60 2011 463
55. P. Vavassori, A. Mencarelli, B. Renga, E. Distrutti, and S. Fiorucci The bile acid receptor FXR is a modulator of intestinal innate immunity J. Immunol. 183 2009 6251
56. R.R.M. Maran, A. Thomas, M. Roth, Z. Sheng, N. Esterly, D. Pinson, X. Gao, Y. Zhang, V. Ganapathy, and F.J. Gonzalez Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development J. Pharmacol. Exp. Ther. 328 2009 469
57. S. Modica, S. Murzilli, L. Salvatore, D.R. Schmidt, and A. Moschetta Nuclear bile acid receptor FXR protects against intestinal tumorigenesis Cancer Res. 68 2008 9589
58. F. Yang, X. Huang, T. Yi, Y. Yen, D.D. Moore, and W. Huang Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor Cancer Res. 67 2007 863
59. N. Liu, Z. Meng, G. Lou, W. Zhou, X. Wang, Y. Zhang, L. Zhang, X. Liu, Y. Yen, L. Lai, B.M. Forman, Z. Xu, R. Xu, and W. Huang Hepatocarcinogenesis in FXR -/- mice mimics human HCC progression that operates through HNF1alpha regulation of FXR expression Mol. Endocrinol. 26 2012 775 785
60. G.A. De, F. Touri, C.A. Maurer, A. Perez, O. Maurhofer, G. Ventre, C.L. Bentzen, E.J. Niesor, and J.F. Dufour The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer Dig. Dis. Sci. 49 2004 982 989
61. S. Lax, G. Schauer, K. Prein, M. Kapitan, D. Silbert, A. Berghold, A. Berger, and M. Trauner Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis Int. J. Cancer 130 2012 2232 2239
62. A. Wolfe, A. Thomas, G. Edwards, R. Jaseja, G.L. Guo, and U. Apte Increased activation of the Wnt/beta-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice J. Pharmacol. Exp. Ther. 338 2011 12 21
63. Y. Xu, T. Watanabe, T. Tanigawa, H. Machida, H. Okazaki, H. Yamagami, K. Watanabe, K. Tominaga, Y. Fujiwara, N. Oshitani, and T. Arakawa Bile acids induce cdx2 expression through the farnesoid X receptor in gastric epithelial cells J. Clin. Biochem. Nutr. 46 2010 81 86
64. A. Capello, L.M. Moons, A. Van de Winkel, P.D. Siersema, D.H. van, E.J. Kuipers, and J.G. Kusters Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus Am. J. Gastroenterol. 103 2008 1510 1516
65. G.A. De, J.M. Dumonceau, F. Bruttin, A. Vonlaufen, I. Morard, L. Spahr, L. Rubbia-Brandt, J.L. Frossard, W.N. Dinjens, P.S. Rabinovitch, and A. Hadengue Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro Mol. Cancer 5 2006 48
66. K.D. Lindor Farnesoid X receptor agonists for primary biliary cirrhosis Curr. Opin. Gastroenterol. 27 2011 285 288
67. A. Akwabi-Ameyaw, J.Y. Bass, R.D. Caldwell, J.A. Caravella, L. Chen, K.L. Creech, D.N. Deaton, K.P. Madauss, H.B. Marr, R.B. McFadyen, A.B. Miller, F. Navas III, D.J. Parks, P.K. Spearing, D. Todd, S.P. Williams, and W.G. Bruce FXR agonist activity of conformationally constrained analogs of GW 4064 Bioorg. Med. Chem. Lett. 19 2009 4733 4739
68. T.G. Hofmann, and M.L. Schmitz The promoter context determines mutual repression or synergism between NF-κB and the glucocorticoid receptor Biol. Chem. 383 2002 1947 1951
69. Y. Wang, J.J. Zhang, W. Dai, K.Y. Lei, and J.W. Pike Dexamethasone potently enhances phorbol ester-induced IL-1beta gene expression and nuclear factor NF-kappaB activation J. Immunol. 159 1997 534
70. J.C. Webster, R.M. Huber, R.L. Hanson, P.M. Collier, T.F. Haws, J.K. Mills, T.C. Burn, and E.A. Allegretto Dexamethasone and tumor necrosis factor-α act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types Endocrinology 143 2002 3866
71. H.K. Chong, A.M. Infante, Y.K. Seo, T.I. Jeon, Y. Zhang, P.A. Edwards, X. Xie, and T.F. Osborne Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1 Nucleic Acids Res. 38 2010 6007
72. C.S. Song, I. Echchgadda, B.S. Baek, S.C. Ahn, T. Oh, A.K. Roy, and B. Chatterjee Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor J. Biol. Chem. 276 2001 42549
73. B.A. Laffitte, H.R. Kast, C.M. Nguyen, A.M. Zavacki, D.D. Moore, and P.A. Edwards Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor J. Biol. Chem. 275 2000 10638
74. J. Lee, S. Seok, P. Yu, K. Kim, Z. Smith, M. Rivas-Astroza, S. Zhong, and J.K. Kemper Genomic analysis of hepatic farnesoid X receptor binding sites reveals altered binding in obesity and direct gene repression by farnesoid X receptor in mice Hepatology 56 2012 108 117
75. A.M. Thomas, S.N. Hart, B. Kong, J. Fang, X.B. Zhong, and G.L. Guo Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine Hepatology 51 2010 1410 1419
76. H.K. Chong, J. Biesinger, Y.K. Seo, X. Xie, and T.F. Osborne Genome-wide analysis of hepatic LRH-1 reveals a promoter binding preference and suggests a role in regulating genes of lipid metabolism in concert with FXR BMC Genomics 13 2012 51
77. H. Shen, Y. Zhang, H. Ding, X. Wang, L. Chen, H. Jiang, and X. Shen Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter Cell. Physiol. Biochem. 22 2008 001 014
78. A. Dostert, and T. Heinzel Negative glucocorticoid receptor response elements and their role in glucocorticoid action: transcription factors as targets of novel therapeutic approaches of autoimmune diseases Curr. Pharm. Des. 10 2004 2807 2816
79. M. Surjit, K.P. Ganti, A. Mukherji, T. Ye, G. Hua, D. Metzger, M. Li, and P. Chambon Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor Cell 145 2011 224 241
80. G. Pascual, and C.K. Glass Nuclear receptors versus inflammation: mechanisms of transrepression Trends Endocrinol. Metab. 17 2006 321 327
81. Y. Kamei, L. Xu, T. Heinzel, J. Torchia, R. Kurokawa, B. Gloss, S.C. Lin, R.A. Heyman, D.W. Rose, and C.K. Glass A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors Cell 85 1996 403 414
82. M.G. Rosenfeld, V.V. Lunyak, and C.K. Glass Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response Genes Dev. 20 2006 1405
83. Y. Lu, J.M. Heydel, X. Li, S. Bratton, T. Lindblom, and A. Radominska-Pandya Lithocholic acid decreases expression of UGT2B7 in Caco-2 cells: a potential role for a negative farnesoid X receptor response element Drug Metab. Dispos. 33 2005 937 946
84. M. Miyata, Y. Matsuda, H. Tsuchiya, H. Kitada, T. Akase, M. Shimada, K. Nagata, F.J. Gonzalez, and Y. Yamazoe Chenodeoxycholic acid-mediated activation of the farnesoid X receptor negatively regulates hydroxysteroid sulfotransferase Drug Metab. Pharmacokinet. 21 2006 315 323
85. J.W. Gaubatz, C. Heideman, A.M. Gotto, J.D. Morrisett, and G.H. Dahlen Human plasma lipoprotein [a]. Structural properties J. Biol. Chem. 258 1983 4582
86. G.M. Kostner, P. Avogaro, G. Cazzolato, E. Marth, G. Bittolo-Bon, and G.B. Qunici Lipoprotein Lp(a) and the risk for myocardial infarction Atherosclerosis 38 1981 51 61
87. G.G. Rhoads, G. Dahlen, K. Berg, N.E. Morton, and A.L. Dannenberg Lp (a) lipoprotein as a risk factor for myocardial infarction JAMA 256 1986 2540
88. I. Chennamsetty, T. Claudel, K.M. Kostner, A. Baghdasaryan, D. Kratky, S. Levak-Frank, S. Frank, F.J. Gonzalez, M. Trauner, and G.M. Kostner Farnesoid X receptor represses hepatic human APOA gene expression J. Clin. Invest. 109 2011 3724 3734
89. G. Schmitz, T. Langmann, and S. Heimerl Role of ABCG1 and other ABCG family members in lipid metabolism J. Lipid Res. 42 2001 1513
90. T. Claudel, E. Sturm, H. Duez, I.P. Torra, A. Sirvent, V. Kosykh, J.C. Fruchart, J. Dallongeville, D.W. Hum, and F. Kuipers Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-1 transcription via a negative FXR response element J. Clin. Invest. 109 2002 961 972
91. C. Gardes, D. Blum, K. Bleicher, E. Chaput, M. Ebeling, P. Hartman, C. Handschin, H. Richter, and G.M. Benson Studies in mice, hamsters, and rats demonstrate that repression of hepatic apoA-I expression by taurocholic acid in mice is not mediated by the farnesoid-X-receptor J. Lipid Res. 52 2011 1188
92. A. Milona, B.M. Owen, J.F.L. Cobbold, E.C.L. Willemsen, I.J. Cox, M. Boudjelal, W. Cairns, K. Schoonjans, S.D. Taylor Robinson, and L.W.J. Klomp Raised hepatic bile acid concentrations during pregnancy in mice are associated with reduced farnesoid X receptor function Hepatology 52 2010 1341 1349
93. B.K. De, W. Vanden Berghe, and G. Haegeman The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression Endocr. Rev. 24 2003 488 522
94. X.X. Wang, T. Jiang, Y. Shen, L. Adorini, M. Pruzanski, F.J. Gonzalez, P. Scherzer, L. Lewis, S. Miyazaki-Anzai, and M. Levi The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria Am. J. Physiol. Renal Physiol. 297 2009 F1587 F1596
95. Y.D. Wang, W.D. Chen, M. Wang, D. Yu, B.M. Forman, and W. Huang Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response Hepatology 48 2008 1632 1643
96. T. Frankenberg, T. Miloh, F.Y. Chen, M. Ananthanarayanan, A.Q. Sun, N. Balasubramaniyan, I. Arias, K.D.R. Setchell, F.J. Suchy, and B.L. Shneider The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor Hepatology 48 2008 1896 1905
97. R. Gineste, A. Sirvent, R. Paumelle, S. Helleboid, A. Aquilina, R. Darteil, D.W. Hum, J.C. Fruchart, and B. Staels Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity Mol. Endocrinol. 22 2008 2433
98. J.K. Kemper, Z. Xiao, B. Ponugoti, J. Miao, S. Fang, D. Kanamaluru, S. Tsang, S.Y. Wu, C.M. Chiang, and T.D. Veenstra FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states Cell Metab. 10 2009 392 404
99. N. Balasubramaniyan, M. Ananthanarayanan, and F.J. Suchy Direct methylation of FXR by Set7/9, a lysine methyltransferase, regulates the expression of FXR target genes Am. J. Physiol. Gastrointest. Liver Physiol. 302 2012 G937 G947
100. E. Treuter, and N. Venteclef Transcriptional control of metabolic and inflammatory pathways by nuclear receptor SUMOylation Biochim. Biophys. Acta 1812 2011 909 918
101. V. Chandra, P. Huang, Y. Hamuro, S. Raghuram, Y. Wang, T.P. Burris, and F. Rastinejad Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex on DNA Nature 456 2008 350 356
102. M. Downes, M.A. Verdecia, A.J. Roecker, R. Hughes, J.B. Hogenesch, H.R. Kast-Woelbern, M.E. Bowman, J.L. Ferrer, A.M. Anisfeld, P.A. Edwards, J.M. Rosenfeld, J.G. Alvarez, J.P. Noel, K.C. Nicolaou, and R.M. Evans A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR Mol. Cell 11 2003 1079 1092
103. J.A. Holt, G. Luo, A.N. Billin, J. Bisi, Y.Y. McNeill, K.F. Kozarsky, M. Donahee, D.Y. Wang, T.A. Mansfield, S.A. Kliewer, B. Goodwin, and S.A. Jones Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis Genes Dev. 17 2003 1581 1591
104. T. Li, M. Matozel, S. Boehme, B. Kong, L.M. Nilsson, G. Guo, E. Ellis, and J.Y. Chiang Overexpression of cholesterol 7alpha-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis Hepatology 53 2011 996 1006
105. J.F. Landrier, J.J. Eloranta, S.R. Vavricka, and G.A. Kullak-Ublick The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes Am. J. Physiol. Gastrointest. Liver Physiol. 290 2006 G476 G485
106. M.J. Evans, P.E. Mahaney, L. Borges-Marcucci, K. Lai, S. Wang, J.A. Krueger, S.J. Gardell, C. Huard, R. Martinez, G.P. Vlasuk, and D.C. Harnish A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia Am. J. Physiol. Gastrointest. Liver Physiol. 296 2009 G543 G552